Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 2/20 | 0.44 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | PPOX | P50336 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | STAT3 | P40763 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27263256 | 0.92 | GAA (0.42) | P2RX3P2RX2NPC1GAATAAR1 | |
| SCHEMBL8375911 | 0.85 | GAA (0.40) | P2RX3P2RX2NPC1GAATAAR1 | |
| SCHEMBL29328271 | 0.85 | P2RX3 (0.44) | P2RX3P2RX2NPC1GAATAAR1 | |
| SCHEMBL5166833 | 0.84 | P2RX3 (0.45) | P2RX3P2RX2GAAMAPTPOLB | |
| SCHEMBL14039591 | 0.82 | NPC1 (0.52) | P2RX3P2RX2NPC1GAATAAR1 | |
| SCHEMBL21142303 | 0.82 | GAA (0.48) | P2RX3P2RX2GAAMAPTPOLB | |
| SCHEMBL16940691 | 0.79 | LMNA (0.43) | MAPTLMNATP53HPGDSMN1; SMN2 | |
| SCHEMBL13178784 | 0.78 | GAA (0.46) | P2RX3P2RX2NPC1GAATAAR1 | |
| SCHEMBL12190518 | 0.78 | P2RX3 (0.48) | P2RX3P2RX2GAAPOLBRAB9A | |
| SCHEMBL13059718 | 0.78 | GAA (0.48) | P2RX3P2RX2GAAMAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210052612-A1 | PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS | CHEMOCENTRYX, INC. | 2021-02-25 | — | — | US | disclosed |
| US-10828285-B2 | Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors | CHEMOCENTRYX, INC. (US) | 2020-11-10 | — | — | US | disclosed |
| WO-2019195159-A1 | PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
| US-20190192491-A1 | DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS | CHEMOCENTRYX, INC. | 2019-06-27 | — | — | US | disclosed |
| US-7435831-B2 | Bicyclic and bridged nitrogen heterocycles | CHEMOCENTRYX, INC. (US) | 2008-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190192491-A1 | DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS | C5AR1, C5AR2, C3AR1 | P2RX3 159/4885P2RX2 239/4885NPC1 1260/4885 |
| US-10828285-B2 | Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors | C5AR1, C5AR2, C3AR1 | P2RX3 159/4885P2RX2 239/4885NPC1 1260/4885 |
| US-20210052612-A1 | PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS | C5AR2, C5AR1, C3AR1 | P2RX3 115/4885P2RX2 94/4885NPC1 2030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.